Latest Mantle cell lymphoma Stories
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh,
NEWTOWN, Pa., March 11, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of specialized outsourced clinical
WASHINGTON, March 10, 2014 /PRNewswire-USNewswire/ -- A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment
Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22,
Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S.
CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients WHITE PLAINS, N.Y., Feb. 12, 2014 /PRNewswire/ -- Today's U.S.
HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S.